Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Beta-Thioguanine Deoxyriboside

Small molecule · Cytotoxic, directed at DNA · developed by Maia Biotechnology

Phase 3 Most advanced trial
MAIA Developer
2 Registered trials

What is Beta-Thioguanine Deoxyriboside?

Beta-thioguanine deoxyriboside is a thiopurine nucleoside derivative that is incorporated into DNA after conversion to its triphosphate form, inhibiting DNA replication. It is cytotoxic to leukemia cells and is being studied in non-small-cell lung cancer and hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
6-Thio-2'-Deoxyguanosine, ateganosine
Drug type
Small molecule
Targets
DNA
Mechanism
Cytotoxic, directed at DNA
Pathways
DNA replication inhibition
Therapy area
Oncology
Developer
Maia Biotechnology (MAIA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06908304 Phase 3 Carcinoma, Non-Small -Cell Lung Recruiting MAIA
NCT07446257 Early Phase 1 Resectable Hepatocellular Carcinoma Recruiting MAIA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Non-Small -Cell LungResectable Hepatocellular Carcinoma

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MAIA page.

Follow MAIA, the company behind Beta-Thioguanine Deoxyriboside

See MAIA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MAIA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.